The utility of pharmacokinetic–pharmacodynamic modeling in the discovery and optimization of selective S1P₁ agonists

References

• Albert R, Hinterding K, Brinkmann V, Guerini D, Müller-Hartwieg C, Knecht H, Simeon C, Streiff M, Wagner T, Welzenbach K, Zécri F, Zollinger M, Cooke N, Francotte E. (2005). Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 48:5373–5377.
   PubMed Web of Science ®Google Scholar
• Bayliss MK, Bell JA, Jenner WN, Wilson K. (1990). Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. Biochem Soc Trans 18:1198–1199.
   PubMedGoogle Scholar
• Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T. (2003). Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278:47408–47415.
   PubMed Web of Science ®Google Scholar
• Bolli MH, Lescop C, Nayler O. (2011). Synthetic sphingosine 1-phosphate receptor modulators–opportunities and potential pitfalls. Curr Top Med Chem 11:726–757.
   Google Scholar
• Budde K, Schütz M, Glander P, Peters H, Waiser J, Liefeldt L, Neumayer HH, Böhler T. (2006). FTY720 (fingolimod) in renal transplantation. Clin Transplant 20 17:17–24.
   Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Demont E, Andrews B, Bit R, Campbell C, Cooke J, Deeks N, Desai S, Dowell S, Gaskin, P, Gray J, Haynes A, Holmes D, Kumar H, Morse M, Osborne G, Panchal T, Patel B, Perboni A, Taylor S, Watson R, Witherington J, Willis R. (2011). Discovery of a selective S1P1 receptor agonist efficacious at low oral dose and devoid of effects on heart rate. ACS Med Chem Lett 2:444–449.
   Google Scholar
• Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer II, Tian M, West S, White V, Xie J, Proia RL, Mandala S. (2004). Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309:758–768.
   PubMed Web of Science ®Google Scholar
• Gergely P, Wallström E, Nuesslein-Hildesheim B, Bruns C, Zécri F, Cooke N, Traebert M, Tuntland T, Rosenberg M, Saltzman M. (2009). Phase I study with selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult Scler 15:S31–S150.
   Google Scholar
• Gerlowski LE, Jain RK. (1983). Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103–1127.
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–1479.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–533.
   PubMed Web of Science ®Google Scholar
• Keldenich J. (2004). Prediction of human clearance (CL) and volume of distribution (VD). Drug Discov Today Technol 1:389–395.
   Google Scholar
• Lavé T, Coassolo P, Reigner B. (1999). Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 36:211–231.
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59–98.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• Marsolais D, Rosen H. (2009). Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 8:297–307.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355–360.
   PubMed Web of Science ®Google Scholar
• Meno-Tetang GM, Lowe PJ. (2005). On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 96:182–192.
   PubMed Web of Science ®Google Scholar
• Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, Jusko WJ. (2006). Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34:1480–1487.
   PubMed Web of Science ®Google Scholar
• Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H. (2004). Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839–13848.
   PubMed Web of Science ®Google Scholar
• Skerjanec A, Tedesco H, Neumayer HH, Cole E, Budde K, Hsu CH, Schmouder R. (2005). FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J Clin Pharmacol 45:1268–1278.
   PubMed Web of Science ®Google Scholar
• Slayter KL, Ludwig EA, Lew KH, Middleton E Jr, Ferry JJ, Jusko WJ. (1996). Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 59:312–321.
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929–939.
   PubMed Web of Science ®Google Scholar
• Summerfield S, Jeffrey P. (2009). Discovery DMPK: changing paradigms in the eighties, nineties and noughties. Expert Opin Drug Discov 4:207–218.
   PubMed Web of Science ®Google Scholar
• Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J. (2004). Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 93:2108–2123.
   PubMed Web of Science ®Google Scholar
• van Der Lee MM, Bras M, van Koppen CJ, Zaman GJ. (2008). β-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1. J Biomol Screen 13:986–998.
   PubMed Web of Science ®Google Scholar
• Wei SH, Rosen H, Matheu MP, Sanna MG, Wang SK, Jo E, Wong CH, Parker I, Cahalan MD. (2005). Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 6:1228–1235.
   PubMed Web of Science ®Google Scholar